Aiolos Bio’s Post

📢 Attention Pharma Enthusiasts! 🌟 Great news! Episode 2 of Pharma Delta's blog series is now live! 💊✨ Discover the latest buzz and insights shaping the pharmaceutical industry. Dive into cutting-edge innovations, strategic collaborations, and more. Don't miss out on staying informed! Read Episode 2 here: https://lnkd.in/dzu33R6N Stay ahead with Pharma Delta. Let's explore the future of healthcare together! 💡🌐 #PharmaDelta #pharmaceutical #pharmaindustry

𝐓𝐡𝐲𝐦𝐢𝐝𝐲𝐥𝐚𝐭𝐞 𝐒𝐲𝐧𝐭𝐡𝐚𝐬𝐞 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 2024-2031 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/dSAzKMUt #ThymidylateSynthaseInhibitor Market Size is predicted to grow at a 6.0% CAGR during the forecast period for 2024-2031. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: ▪ Teva Pharmaceuticals ▪ Fresenius Kabi ▪ Cadila Pharmaceuticals Limited ▪ Eli Lilly and Company ▪ Novartis ▪ Amgen ▪ AstraZeneca ▪ Sanofi ▪ Bristol Myers Squibb ▪ Merck Group ▪ AbbVie ▪ Roche ▪ Johnson & Johnson ▪ Viatris ▪ Abbott ▪ Pfizer ▪ Accord Healthcare ▪ GSK ▪ Sun Pharmaceutical Sdn Bhd ▪ Bayer ▪ Baxter Pharmaceuticals #Injection #Tablets #HospitalTreatment #ClinicApplications #HealthcareMarket 

Polpharma Biologics, a biotech company specializing in biosimilars, announced positive topline results for their biosimilar candidate PB016, compared to the reference drug Entyvio® (vedolizumab). The study involved 120 healthy subjects and showed PB016's comparability in pharmacokinetics (PK) and pharmacodynamics (PD), with no safety concerns or immunogenicity issues. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 𝐬𝐞𝐞𝐬 𝐏𝐁𝟎𝟏𝟔 𝐚𝐬 𝐚 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐜𝐨𝐬𝐭-𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐦𝐢𝐥𝐥𝐢𝐨𝐧𝐬 𝐬𝐮𝐟𝐟𝐞𝐫𝐢𝐧𝐠 𝐟𝐫𝐨𝐦 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐛𝐨𝐰𝐞𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 (𝐈𝐁𝐃). 𝐖𝐢𝐭𝐡 𝐏𝐁𝟎𝟏𝟔 𝐞𝐧𝐭𝐞𝐫𝐢𝐧𝐠 𝐥𝐚𝐭𝐞-𝐬𝐭𝐚𝐠𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭, 𝐏𝐨𝐥𝐩𝐡𝐚𝐫𝐦𝐚 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐚𝐢𝐦𝐬 𝐭𝐨 𝐬𝐞𝐜𝐮𝐫𝐞 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐟𝐨𝐫 𝐭𝐡𝐢𝐬 𝐚𝐬𝐬𝐞𝐭. Further clinical trials are underway to provide more evidence on PB016's efficacy and safety in patients with ulcerative colitis (UC). 𝐕𝐞𝐝𝐨𝐥𝐢𝐳𝐮𝐦𝐚𝐛, 𝐭𝐡𝐞 𝐭𝐚𝐫𝐠𝐞𝐭 𝐝𝐫𝐮𝐠, 𝐢𝐬 𝐚 𝐦𝐨𝐧𝐨𝐜𝐥𝐨𝐧𝐚𝐥 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐟𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐔𝐂, 𝐂𝐫𝐨𝐡𝐧'𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞, 𝐚𝐧𝐝 𝐩𝐨𝐮𝐜𝐡𝐢𝐭𝐢𝐬 𝐢𝐧 𝐯𝐚𝐫𝐢𝐨𝐮𝐬 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬. Polpharma Biologics, with a focus on expanding access to biological medicines, is actively developing a pipeline of biosimilars across multiple therapeutic areas. #marketintelligence #competitiveintelligence #marketsmind #biosimilars #pharmaceutical

✨ Stay ahead with the latest trends and insights in the world of pharmaceuticals! Today's Pharma Daily Digest brings you key commercial and regulatory updates in the industry. Commercial 💰 1. Exelixis and Merck partnered to evaluate zanzalintinib with KEYTRUDA for head and neck cancer and WELIREG for renal cell carcinoma. The collaboration includes a phase 3 trial for head and neck cancer and multiple trials for renal cell carcinoma, with shared funding. Exelixis retains global rights to zanzalintinib, while Merck supplies KEYTRUDA and sponsors key trials 2. Ailux Biologics signed a non-exclusive agreement with Janssen Biotech, Inc. to use its XtalFold™ AI platform for biologics discovery and engineering. XtalFold™ excels in modeling complex biomolecular interactions, speeding up biologics innovation 3. Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome 4. FDA to reconsider removal of Eli Lilly and Company's GLP-1 drug Tirzepatide from shortage list, a win for compounding pharmacies 5. Sanofi lands on private equity firm Clayton, Dubilier & Rice as potential buyer of consumer health unit   Regulatory 💼 1. The FDA granted Fast Track status to ALXN2220 after Phase 1b results showed its potential to reduce cardiac amyloid deposits and improve heart function in ATTR-CM patients. 2. Bayer submitted an EU application for a 3rd indication of darolutamide, based on positive Phase 3 ARANOTE trial results (darolutamide + ADT reduced risk of radiological progression or death by 46% in metastatic hormone-sensitive prostate cancer compared to placebo + ADT) Challenges / Set-backs 🛑 1. Transgene's TG4001 viral cancer vaccine failed to meet its primary endpoint in a phase 2 trial for solid tumors, showing no significant improvement in progression-free survival when combined with Bavencio 2.  High-Profile Drug Withdrawals: Pfizer's Oxbryta and Biogen's Aduhelm Pulled from Market Due to Safety Concerns 💡 Don't forget to sign up for daily updates within the pharma and biotech industry. #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #pfizer #biogen #bayer #Sanofi #lundbeck #Ailux #merck #Exelixis

Recently, Altimmune, a clinical-stage biopharmaceutical company, provided updates on its latest peptide-based drug development efforts. The company's lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist designed for treating obesity and metabolic-associated steatohepatitis (MASH). In clinical trials, pemvidutide has shown significant promise by demonstrating weight loss and reductions in liver fat, triglycerides, and LDL cholesterol. These developments are part of Altimmune's broader strategy to leverage next-generation peptide therapeutics to address unmet medical needs in chronic metabolic diseases. Another noteworthy update comes from Structure Therapeutics, which has been advancing its drug discovery efforts focused on GPCR-targeted therapies. This platform aims to develop small molecule compounds that surpass traditional peptide therapies' limitations, potentially expanding access to more patients worldwide. These developments highlight ongoing advancements in peptide-based drug discovery, showcasing the potential for innovative treatments in metabolic diseases and other therapeutic areas. https://lnkd.in/gksFbNFK

🧫🚀 Today, SciRhom, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced the closing of a €63 million (US$ 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including HTGF | High-Tech Gründerfonds and PhiFund Ventures from New York, USA. The new funds will be used to accelerate and broaden the impact of the company’s innovative therapeutic strategy in autoimmune disorders. The first clinical study evaluating SR-878, a highly specific monoclonal antibody for iRhom2, is expected to start dosing in the second half of 2024. 💬 Co-founder Dr. Jens Ruhe, Managing Director & COO of SciRhom says: “Since its foundation, SciRhom has applied rigorous science to establish a leading position in iRhom2-targeting biopharmaceuticals including a comprehensive IND/CTA-enabling data and CMC package and strong patent protection. Now is the time to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments.” 🗨 Frank Hensel, Principal at HTGF comments: "We are pleased that SciRhom attracted a consortium of renowned investors and raised significant funds to perform state-of-the-art clinical development of its first-in-class monoclonal antibody. Targeting iRhom-2 holds great promise to be the next game changer in treating autoimmune diseases and we hope to see clinical validation soon." 👏 HTGF congratulates! Learn more: https://lnkd.in/ee-vyZex

Bioconjugates Meet and Promise to Exceed Expectations One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. As cancer-fighting antibody- drug conjugates become established, bioconjugates based on non-antibody proteins and alternative payloads are emerging.

check out our top biotech news today Investorideas.com- News that inspires big investing ideas Biotech/Pharma Stocks to Watch Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), Soligenix, Inc. (Nasdaq: SNGX), Takeda (NYSE: TAK), Pfizer (NASDAQ: PFE) The Race For Solutions for Cutaneous T-Cell #Lymphoma (CTCL) #biotech #biotechnologystocks #pharma   #stockstowatch #stockstotrade #stocksinfocus July 18, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (Nasdaq:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. Looking specifically at the opportunity for Cutaneous T-Cell Lymphoma (CTCL) treatments, the market was approximately USD 399 Million in 2021 says Delveinsight. "CTCL has an active pipeline as many pharmaceutical companies are working toward developing an effective and affordable therapy. The disease has a tendency to show resistance to medications creating a need for a more efficacious and effective drug." The US Cutaneous T-cell Lymphoma Market is projected to reach $1.38 Billion by 2030 reports Insights10. Citius Pharmaceuticals (Nasdaq:CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate to address this unmet need. paid news dissemination

Doer Bio completes enrollment in phase 1b/2a trial of DR10624 in obese subjects with modest hypertriglyceridemia

Sanofi and Inhibrx, Inc., a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which Sanofi has agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. Houman Ashrafian, Head of Research and Development, Sanofi: “The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products. With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities.” INBRX-101 has successfully completed a Phase 1 trial, demonstrating positive results in terms of safety and pharmacokinetics and is currently enrolling a Phase 2 clinical trial to further evaluate the potential of INBRX-101 as a treatment for AATD. If successful, INBRX-101 could offer a significant improvement in the treatment options and quality of life for AATD patients.  #raredisease #AATD #acquisition #Inhibrx #Sanofi  👉 Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline